Haselmeier Announces the Launch of INSUPen EZ by Biocon
Haselmeier recently announced that Biocon, one of Asia’s premier biotechnology companies, has just launched INSUPen EZ in India. The INSUPen EZ is a second- generation pen and follows on the success of Biocon’s premier insulin delivery device INSUPen. Under the terms of the agreement between the two companies, Biocon has worldwide distribution rights to INSUPen EZ, for use with Biocon’s insulin, Basalog and Insugen, and insulin analogues.
The INSUPen EZ is a reusable insulin pen, based on Haselmeier’s new i-pen² platform and is designed to be easy to use and provide a smoother injection experience. It can deliver insulin doses from 1 unit (0.01 ml) to 60 units (0.60 ml) in increments of 1 unit (0.01 ml) with insulin preparations of 100 IU/ml and features an audible sound when dialing a dose for accurate and reliable dosing. The INSUPen EZ is available in an egg shell white thermo-resistant, light-weight Terluran body and is available in different colours for differentiating insulins.
The launch of INSUPen EZ, represents another milestone in the long-standing relationship between Biocon and Haselmeier. “Haselmeier is delighted to collaborate with Biocon and contribute to the market introduction of INSUPen EZ”, says Sandra de Haan, Director Project Management at Haselmeier GmbH.
Founded in Stuttgart in 1920, Haselmeier is one of the leading designers and manufacturers of injection systems. Haselmeier’s devices feature unique function, design, and technology and are marketed by leading pharmaceutical and biotechnology companies around the world. At five locations on three continents, Haselmeier develops and produces innovative technology for drug delivery which enhances the health and daily life of the patient.
Established in 1978, Biocon Limited is India’s largest biotechnology company by revenue. The Group, promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon’s value chain traverses the entire length of discovery, development, and commercialization of novel therapeutics.
Total Page Views: 1711
